NEONC TECHNOLOGIES HOLDINGS, INC.
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI): 4 pipeline candidates · 1 upcoming catalyst · ~0 mo cash runway · 4 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
0.3 months
D/E -1.25 · 0% dilution
Lead: Phase 1/Phase 2
4 candidates
1 upcoming, next in ~12d
10 buys · 0 sells (180d)
A transparent, data-derived signal for NEONC TECHNOLOGIES HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$139.7M
Cash
$139K
Quarterly Burn
$7.0M
Runway
0.3 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| folfiri protocol | Phase 1/Phase 2 |
| neo100 | Phase 2 |
| neo212 | Phase 1/Phase 2 |
| perillyl alcohol | Phase 1/Phase 2 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$11.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 431,400 | $3.0M |
| bank of america corp /de/ | 235,396 | $1.7M |
| blackrock, inc. | 155,838 | $1.1M |
| hudson bay capital management lp | 147,360 | $962K |
| geode capital management, llc | 126,853 | $890K |
| millennium management llc | 119,249 | $836K |
| susquehanna international group, llp | 91,036 | $638K |
| vanguard fiduciary trust co | 56,016 | $393K |
| morgan stanley | 51,922 | $364K |
| 683 capital management, llc | 50,000 | $351K |
Showing top 10 of 25 institutional holders of NEONC TECHNOLOGIES HOLDINGS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in NEONC TECHNOLOGIES HOLDINGS, INC.'s pipeline?
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NEONC TECHNOLOGIES HOLDINGS, INC.'s lead drug candidate?
NEONC TECHNOLOGIES HOLDINGS, INC.'s most advanced tracked candidate is folfiri protocol (Phase 1/Phase 2) for Diffuse Astrocytoma, IDH-Mutant.
What is NEONC TECHNOLOGIES HOLDINGS, INC.'s next catalyst?
NEONC TECHNOLOGIES HOLDINGS, INC.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: neo100" — expected June 30, 2026.
What is NEONC TECHNOLOGIES HOLDINGS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NEONC TECHNOLOGIES HOLDINGS, INC. has approximately 0.3 months of cash runway.
What is NEONC TECHNOLOGIES HOLDINGS, INC.'s market capitalization?
NEONC TECHNOLOGIES HOLDINGS, INC.'s market capitalization is approximately $139.7M.
Get the full picture on NEONC TECHNOLOGIES HOLDINGS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.